FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891728068> ?p ?o ?g. }

• W2891728068 endingPage "e51" @default.
• W2891728068 startingPage "e39" @default.
• W2891728068 abstract "Introduction Preclinically, high epidermal growth factor receptor 1 (FGFR1) messenger RNA (FGFR1-MRNA) and FGFR1 amplification (FGFR1-AMP) predicted sensitivity to fibroblast growth factor receptor inhibitors in non–small-cell lung cancer and small-cell lung cancer cell lines. KRAS mutations did not preclude sensitivity. Patients and Methods Metastatic EGFR- and ALK-negative lung cancers were screened for FGFR1-MRNA by in-situ hybridization (ISH) and FGFR1-AMP by silver in-situ hybridization (SISH). Patients with positive findings were offered ponatinib, a multi–kinase inhibitor of FGFR1-4. Differences in overall survival (OS) between cohorts were assessed by the log-rank test. Association of FGFR1 positivity with clinicopathologic features were assessed by Fisher exact test and Kruskal-Wallis rank sum test. Results A total of 171 cases were prescreened: 9 (7.3%) of 123 SISH+; 53 (42.1%) of 126 ISH+; and 6 cases concordantly positive for SISH and ISH. SISH+ cases had fewer coincident KRAS mutations (P = .03) than SISH− cases, and ISH+ cases had worse OS (P = .020) than ISH− cases. Data distributions suggested a distinct higher positivity cut point for FGFR1 ISH (≥ 20%), occurring in 29 (23%) of 126 cases, was associated with small-cell lung cancer histology (P = .022), soft tissue metastases (P = .050) and shorter OS (P = .031). Four patients received ponatinib on study: All ISH+ by the initial cut point, 2 of 4 by higher cut point, 1 of 4 SISH+. Tolerability was poor. The best response for the 2 higher ISH cases was stable disease and progressive disease for the 2 lower ISH cases. Conclusion Elevated FGFR1-MRNA is more common than FGFR1-AMP and associated with worse OS. Higher FGFR1 mRNA expression may be associated with a specific phenotype and is worthy of further exploration. Ponatinib's poor tolerance suggests further fibroblast growth factor receptor exploration in ISH+ cases should utilize more selective FGFR1 inhibitors." @default.
• W2891728068 created "2018-09-27" @default.
• W2891728068 creator A5013014678 @default.
• W2891728068 creator A5024457228 @default.
• W2891728068 creator A5042355911 @default.
• W2891728068 creator A5043408743 @default.
• W2891728068 creator A5044311667 @default.
• W2891728068 creator A5052885079 @default.
• W2891728068 creator A5056025427 @default.
• W2891728068 creator A5057844697 @default.
• W2891728068 creator A5065074393 @default.
• W2891728068 creator A5067786581 @default.
• W2891728068 creator A5071851332 @default.
• W2891728068 creator A5082517668 @default.
• W2891728068 date "2019-01-01" @default.
• W2891728068 modified "2023-10-16" @default.
• W2891728068 title "Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib" @default.
• W2891728068 cites W1120062987 @default.
• W2891728068 cites W2000255249 @default.
• W2891728068 cites W2056983875 @default.
• W2891728068 cites W2073031201 @default.
• W2891728068 cites W2096019143 @default.
• W2891728068 cites W2096861064 @default.
• W2891728068 cites W2099530756 @default.
• W2891728068 cites W2101979288 @default.
• W2891728068 cites W2104694028 @default.
• W2891728068 cites W2108927999 @default.
• W2891728068 cites W2111662961 @default.
• W2891728068 cites W2111675538 @default.
• W2891728068 cites W2118696726 @default.
• W2891728068 cites W2120113475 @default.
• W2891728068 cites W2126177831 @default.
• W2891728068 cites W2129360604 @default.
• W2891728068 cites W2132157071 @default.
• W2891728068 cites W2134787029 @default.
• W2891728068 cites W2149662085 @default.
• W2891728068 cites W2159060826 @default.
• W2891728068 cites W2160982674 @default.
• W2891728068 cites W2166084034 @default.
• W2891728068 cites W2275877493 @default.
• W2891728068 cites W2409552123 @default.
• W2891728068 cites W2440186002 @default.
• W2891728068 cites W2550856922 @default.
• W2891728068 cites W2613954421 @default.
• W2891728068 cites W2626344037 @default.
• W2891728068 cites W404741376 @default.
• W2891728068 doi "https://doi.org/10.1016/j.cllc.2018.09.001" @default.
• W2891728068 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6339510" @default.
• W2891728068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297175" @default.
• W2891728068 hasPublicationYear "2019" @default.
• W2891728068 type Work @default.
• W2891728068 sameAs 2891728068 @default.
• W2891728068 citedByCount "11" @default.
• W2891728068 countsByYear W28917280682019 @default.
• W2891728068 countsByYear W28917280682020 @default.
• W2891728068 countsByYear W28917280682021 @default.
• W2891728068 countsByYear W28917280682022 @default.
• W2891728068 crossrefType "journal-article" @default.
• W2891728068 hasAuthorship W2891728068A5013014678 @default.
• W2891728068 hasAuthorship W2891728068A5024457228 @default.
• W2891728068 hasAuthorship W2891728068A5042355911 @default.
• W2891728068 hasAuthorship W2891728068A5043408743 @default.
• W2891728068 hasAuthorship W2891728068A5044311667 @default.
• W2891728068 hasAuthorship W2891728068A5052885079 @default.
• W2891728068 hasAuthorship W2891728068A5056025427 @default.
• W2891728068 hasAuthorship W2891728068A5057844697 @default.
• W2891728068 hasAuthorship W2891728068A5065074393 @default.
• W2891728068 hasAuthorship W2891728068A5067786581 @default.
• W2891728068 hasAuthorship W2891728068A5071851332 @default.
• W2891728068 hasAuthorship W2891728068A5082517668 @default.
• W2891728068 hasBestOaLocation W28917280682 @default.
• W2891728068 hasConcept C121608353 @default.
• W2891728068 hasConcept C126322002 @default.
• W2891728068 hasConcept C142724271 @default.
• W2891728068 hasConcept C143998085 @default.
• W2891728068 hasConcept C170493617 @default.
• W2891728068 hasConcept C191093355 @default.
• W2891728068 hasConcept C2776256026 @default.
• W2891728068 hasConcept C2779438470 @default.
• W2891728068 hasConcept C2779536868 @default.
• W2891728068 hasConcept C2780381907 @default.
• W2891728068 hasConcept C2781187634 @default.
• W2891728068 hasConcept C42362537 @default.
• W2891728068 hasConcept C49418065 @default.
• W2891728068 hasConcept C502942594 @default.
• W2891728068 hasConcept C526805850 @default.
• W2891728068 hasConcept C71924100 @default.
• W2891728068 hasConcept C74373430 @default.
• W2891728068 hasConceptScore W2891728068C121608353 @default.
• W2891728068 hasConceptScore W2891728068C126322002 @default.
• W2891728068 hasConceptScore W2891728068C142724271 @default.
• W2891728068 hasConceptScore W2891728068C143998085 @default.
• W2891728068 hasConceptScore W2891728068C170493617 @default.
• W2891728068 hasConceptScore W2891728068C191093355 @default.
• W2891728068 hasConceptScore W2891728068C2776256026 @default.
• W2891728068 hasConceptScore W2891728068C2779438470 @default.
• W2891728068 hasConceptScore W2891728068C2779536868 @default.
• W2891728068 hasConceptScore W2891728068C2780381907 @default.

• next